Although the effect of EGFR-TKIs in NSCLC patients with wild-type EGFR remains controversial, some clinical data have shown survival benefit derived from EGFR-TKI treatment for patients previously treated with chemotherapy but still developed disease progression [19–22]. Here, EGFR is linked to non-small cell lung carcinoma.